These observations, together with the evidence showing that patients with a high TGF-β mRNA levels in EV could respond to anti-PD-1 antibodies regardless of the type of drug used, reinforces the hypothesis of a predictive role of TGF-β mRNA levels in patients with metastatic melanoma. The gene discussed is TGFB1; the disease is metastatic melanoma.